Literature DB >> 19892898

Diagnosis and new treatments in muscular dystrophies.

A Y Manzur1, F Muntoni.   

Abstract

Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and limb girdle muscular dystrophies (LGMD) represent a significant proportion of paediatric and adult neuromuscular neurology practice. The proactive symptom-based multidisciplinary team (MDT) management and access to non-invasive ventilation have enabled improved survival into adulthood. Nevertheless the severe disability imposed by conditions such as DMD poses a challenge for successful transition of care and management for paediatric and adult neurology teams. DMD is discussed in detail as a paradigm illustrating diagnosis, management and role for different pharmacological interventions to improve survival, but also challenges in adulthood care, and cutting-edge therapies. LGMDs are much rarer than DMD and BMD, and in addition there is a significant genetic and clinical heterogeneity, which leads to diagnostic difficulties. The clinical and laboratory diagnostic features of seven LGMD subtypes are summarised, and their allelic "non-limb girdle" phenotypes are tabulated to illustrate the theme of one gene causing multiple clinical phenotypes, with the aim of refining the clinician's diagnostic approach. The lessons learnt from DMD MDT management to improve survival are broadly applicable to LGMDs with severe motor disability/multisystem complications.

Entities:  

Year:  2009        PMID: 19892898     DOI: 10.1136/jnnp.2008.158329

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

2.  N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.

Authors:  Kelly E Crowe; Guohong Shao; Kevin M Flanigan; Paul T Martin
Journal:  J Neuromuscul Dis       Date:  2016-05-27

3.  Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts.

Authors:  Pavithra S Iyer; Lionel O Mavoungou; Flavio Ronzoni; Joanna Zemla; Emanuel Schmid-Siegert; Stefania Antonini; Laurence A Neff; Olivier M Dorchies; Marisa Jaconi; Malgorzata Lekka; Graziella Messina; Nicolas Mermod
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

4.  Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping.

Authors:  Tania Incitti; Fernanda G De Angelis; Valentina Cazzella; Olga Sthandier; Chiara Pinnarò; Ivano Legnini; Irene Bozzoni
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  Functional in situ assessment of muscle contraction in wild-type and mdx mice.

Authors:  Tammy Tamayo; Eben Eno; Carlos Madrigal; Ahlke Heydemann; Kelly García; Jesús García
Journal:  Muscle Nerve       Date:  2015-10-10       Impact factor: 3.217

6.  A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy.

Authors:  Kumaran Chandrasekharan; Jung Hae Yoon; Ying Xu; Sarah deVries; Marybeth Camboni; Paulus M L Janssen; Ajit Varki; Paul T Martin
Journal:  Sci Transl Med       Date:  2010-07-28       Impact factor: 17.956

7.  Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice.

Authors:  Chady H Hakim; Dongsheng Duan
Journal:  J Appl Physiol (1985)       Date:  2012-12-06

8.  Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.

Authors:  Valentina Cazzella; Julie Martone; Chiara Pinnarò; Tiziana Santini; Shyam Sundar Twayana; Olga Sthandier; Adele D'Amico; Valeria Ricotti; Enrico Bertini; Francesco Muntoni; Irene Bozzoni
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

9.  Dystrophin and utrophin expression require sarcospan: loss of α7 integrin exacerbates a newly discovered muscle phenotype in sarcospan-null mice.

Authors:  Jamie L Marshall; Eric Chou; Jennifer Oh; Allan Kwok; Dean J Burkin; Rachelle H Crosbie-Watson
Journal:  Hum Mol Genet       Date:  2012-07-13       Impact factor: 6.150

10.  Pericytes in Muscular Dystrophies.

Authors:  Louise Anne Moyle; Francesco Saverio Tedesco; Sara Benedetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.